| Gene Symbol | HNRNPA2B1 |
| Full Name | HNRNPA2B1 |
| Aliases | Page for HNRNPA2B1 |
| Chromosome | 7p15.2 |
| Protein Family | HnRNP A/B family |
| Protein Type | Other |
| Target Class | Other |
| Function | Therapeutic agents targeting HNRNPA2B1 would work by modulating its RNA-binding activity, preventing pathological protein aggregation, or reducing the formation of cytoplasmic inclusions associated... |
| Mechanism of Action | Therapeutic agents targeting HNRNPA2B1 would work by modulating its RNA-binding activity, preventing pathological protein aggregation, or reducing the formation of cytoplasmic inclusions associated with neurodegeneration. These drugs could utilize antisense oligonucleotides to reduce HNRNPA2B1 expression or small molecules to inhibit its protein-protein interactions and RNA-binding functions. |
| Druggability | Low (0.35) |
| Clinical Stage | Phase II |
| Molecular Weight | 36 kDa |
| Amino Acids | 341 aa |
| Pathways | RNA transport / hnRNP processing |
| UniProt ID | P22626 |
| NCBI Gene ID | 3181 |
| Ensembl ID | ENSG00000122566 |
| OMIM | 600124 |
| GeneCards | HNRNPA2B1 |
| Human Protein Atlas | HNRNPA2B1 |
| Associated Diseases | ALS, Alzheimer's Disease, Amorphous Aggregates, Amyotrophic Lateral Sclerosis, Cancer |
| Known Drugs/Compounds | G-Quadruplex Structured Dna, Single-Stranded Dna, Ionic Strength, Irinotecan, Viral Genome G-Quadruplex |
| Interactions | IGF2BP1, CSNK2A1, NOTCH1, JUN, RANK, RANKL |
| SciDEX Target | View Target Profile (1 clinical trials) |
| SciDEX Hypotheses | Axonal RNA Transport Reconstitution |
| KG Connections | 421 knowledge graph edges |
| Databases | GeneCardsHPASTRING |